Artificial Intelligence Drug Discovery: Where are We Now?
In the 1960s, pharmaceutical researchers started on a long journey to discover and develop new medicines using computers. These visionary scientists realized that humans assisted by computers could have a tremendous competitive advantage relative to traditional pencil and paper based approaches. Today, computational methods are now routinely used to extract value from the ever increasing volume and diversity of experimental data generated from highly interconnected multidisciplinary collaborators.
Join this webinar to hear the latest trends from drug discovery thought leaders in the industry using AI to model and predict medicinal and biological properties.
Featuring these leading scientists...
Matthew Segall, PhD
CEO at Optibrium Ltd
Matt Segall is the CEO of Optibrium Ltd, which provides integrative, intuitive software for small molecule design, optimisation and data analysis. From advanced artificial intelligence technologies to user-friendly drug design platforms, such as StarDrop™ and Cerella™, all Optibrium products and services are backed up by rigorous scientific research and support scientists in their decision making throughout the drug discovery process.
Dr. Segall has a Masters of Science in Computation from the University of Oxford and a PhD in Theoretical Physics from the University of Cambridge.
Hanjo Kim, PhD
SVP Strategic Planning at Standigm
Hanjo Kim is a Senior Vice President at Standigm, an AI drug discovery company with operations in Seoul (South Korea), Cambridge (UK), and Cambridge (USA). At Standigm, he has held multiple roles, including SVP of Global Strategy, Head of Medicinal Chemistry and Deputy Head of Research.
Dr. Kim received a Bachelor of Science in Chemistry, Masters of Science and PhD in Organic Chemistry degrees from Yonsei University in Korea.
Alpha Lee, PhD
Co-founder & CSO at PostEra
Alpha Lee is the Co-founder and Chief Scientific Officer of PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery. The company focuses on using advances in machine learning to close the Design-Make-Test cycle of Medicinal Chemistry.
Dr. Lee has a Bachelor of Science in Chemistry from Imperial College London and Masters of Mathematical Modeling and Scientific Computing and PhD degrees from University of Oxford.